Market Overview

RXi Pharmaceuticals to Present at ARVO 2014 Annual Meeting

Related RXII
RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board
RXi Pharmaceuticals Initiates First Phase 2 Study with RXI-109

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies today announced that the Company will present at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting.

RXi Pharmaceuticals On Sunday, May 4, 2014, from 3:15 to 5:00 p.m. EDT, Lyn Libertine, M.D., Vice President of Medical Affairs and Safety Assessment at RXi Pharmaceuticals, will present a poster providing an overview of the use of our self-delivering RNAi (sd-rxRNAs®) compounds in the eye. "RXI-109 Treatment for Proliferative Vitreoretinopathy (PVR) and other Ocular Disorders," will be presented during the Retinal Detachment and Allied Diseases session and will be available on the Company's website.

On Thursday, May 8, 2014 at 12:45 p.m. EDT, Michael Byrne, Ph.D., Manager of Pharmacology Research at RXi Pharmaceuticals, will present an update on RXi's work in the area of retinoblastoma, including the gene target being pursued for this indication. Dr. Byrne's presentation, "An Update on the Development of sd‑rxRNA for Retinoblastoma Therapy," will take place during Ocular Tumors-Management and Prognosis session and will be available on the Company's website.

ARVO is the largest and most respected eye and vision research organization in the world. Members include more than 12,750 researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology. This conference is being held May 4-8, 2014 at the Orlando Convention Center, Orlando, Florida. For more information visit: http://www.arvo.org

Posted-In: News Press Releases

 

Related Articles (RXII)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters